Filtered By:
Drug: Eptifibatide

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 64 results found since Jan 2013.

Recombinant Tissue-Type Plasminogen Activator Plus Eptifibatide Versus Recombinant Tissue-Type Plasminogen Activator Alone in Acute Ischemic Stroke: Propensity Score-Matched Post Hoc Analysis Clinical Sciences
Conclusion— r-tPA plus eptifibatide showed a favorable direction of effect that was consistent across multiple approaches for AIS outcome evaluation. A phase III trial to establish the efficacy of r-tPA plus eptifibatide for improving AIS outcomes is warranted.
Source: Stroke - January 26, 2015 Category: Neurology Authors: Adeoye, O., Sucharew, H., Khoury, J., Tomsick, T., Khatri, P., Palesch, Y., Schmit, P. A., Pancioli, A. M., Broderick, J. P., for The CLEAR-ER, IMS III, and ALIAS Part 2 Investigators Tags: Acute Cerebral Infarction, Emergency treatment of Stroke, Thrombolysis Clinical Sciences Source Type: research

Ischemic Stroke After Treatment of Intraprocedural Thrombosis During Stent-Assisted Coiling and Flow Diversion Brief Report
Conclusions—Current protocols for treatment of intraprocedural thrombosis associated with placement of intra-arterial devices were effective in preventing ischemic stroke in ≈80% of cases. Current smoking was the only independent predictor of ischemic stroke.
Source: Stroke - March 27, 2017 Category: Neurology Authors: Nimer Adeeb, Christoph J. Griessenauer, Justin M. Moore, Paul M. Foreman, Hussain Shallwani, Rouzbeh Motiei-Langroudi, Raghav Gupta, Carlos E. Baccin, Abdulrahman Alturki, Mark R. Harrigan, Adnan H. Siddiqui, Elad I. Levy, Christopher S. Ogilvy, Ajith J. Tags: Cerebral Aneurysm, Ischemic Stroke Brief Reports Source Type: research

Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke-Enhanced Regimen Stroke Trial Major Clinical Trial
Conclusions— The combined regimen of intravenous rt-PA and eptifibatide studied in this trial was safe and provides evidence that a phase III trial is warranted to determine efficacy of the regimen. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00894803.
Source: Stroke - August 26, 2013 Category: Neurology Authors: Pancioli, A. M., Adeoye, O., Schmit, P. A., Khoury, J., Levine, S. R., Tomsick, T. A., Sucharew, H., Brooks, C. E., Crocco, T. J., Gutmann, L., Hemmen, T. M., Kasner, S. E., Kleindorfer, D., Knight, W. A., Martini, S., McKinney, J. S., Meurer, W. J., Meye Tags: Emergency treatment of Stroke, Antiplatelets, Thrombolysis Major Clinical Trial Source Type: research

Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial Clinical Sciences
Conclusions— These results demonstrate comparable safety of full-dose r-tPA plus eptifibatide with historical rates of sICH with r-tPA alone and support proceeding with a phase 3 trial evaluating full-dose r-tPA combined with eptifibatide to improve outcomes after AIS.
Source: Stroke - August 24, 2015 Category: Neurology Authors: Adeoye, O., Sucharew, H., Khoury, J., Vagal, A., Schmit, P. A., Ewing, I., Levine, S. R., Demel, S., Eckerle, B., Katz, B., Kleindorfer, D., Stettler, B., Woo, D., Khatri, P., Broderick, J. P., Pancioli, A. M. Tags: Acute Cerebral Infarction, Emergency treatment of Stroke, Thrombolysis Clinical Sciences Source Type: research

A Matched Comparison of Eptifibatide Plus rt-PA Versus rt-PA Alone in Acute Ischemic Stroke
Conclusions: The safety and direction of effect of eptifibatide plus rt-PA were confirmed. A phase III trial is needed to determine the efficacy of eptifibatide plus rt-PA for improving long-term outcomes after AIS.
Source: Journal of Stroke and Cerebrovascular Diseases - February 19, 2014 Category: Neurology Authors: Opeolu Adeoye, William A. Knight, Jane Khoury, Pamela A. Schmit, Heidi Sucharew, Joseph P. Broderick, Arthur M. Pancioli, CLEAR-ER Investigators Tags: Original Articles Source Type: research

Study shows combination stroke therapy safe and effective
The combination of the clot-busting drug tPA with an infusion of the antiplatelet drug eptifibatide dissolves blood clots safely and more quickly than tPA alone, a study led by University of Cincinnati (UC) researchers has found. Results from the study, known as the CLEAR-ER Stroke Trial, are published online in the journal Stroke: Journal of the American Heart Association. UC was the coordinating center for the trial, which included nine medical centers comprising 21 hospitals...
Source: Health News from Medical News Today - August 1, 2013 Category: Consumer Health News Tags: Stroke Source Type: news

Eptifibatide use following emergent carotid stenting in acute anterior circulation ischemic stroke with tandem occlusion
Early revascularization of the extracranial internal carotid artery in acute anterior circulation ischemic stroke (ACIS) is feasible and may improve clinical outcome. When a stent is deployed, antithrombotic agents should be administered peri-procedurally to ensure stent patency. Our institution implemented a protocol for the use of eptifibatide as a means of maintaining stent patency in the treatment of ACIS associated with cervical internal carotid artery occlusion.
Source: Journal of Stroke and Cerebrovascular Diseases - August 15, 2020 Category: Neurology Authors: Nicholas D Osteraas, Richard W Crowley, Nicholas Panos, Rima M Dafer Source Type: research

Combination Therapy of Intravenous Glycoprotein IIB-IIIA Inhibitors and Tissue Plasminogen Activator for Acute Ischemic Stroke (P1.112)
Conclusion Combination of low dose IV tPA with GpIIb/IIIa inhibitor is associated with better functional outcome at 90 days as well as reduction in sICH rates in patients with acute ischemic stroke as compared to 0.9g/kg IVtPA.Disclosure: Dr. Sawhney has nothing to disclose. Dr. Dubey has nothing to disclose. Dr. Banerjee has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Sawhney, A., Dubey, D., Banerjee, C. Tags: Cerebrovascular Disease and Interventional Neurology: Antiplatelet Agents and Miscellaneous Source Type: research

Is Eptifibatide a Viable and Safe Option as Stand-Alone Therapy for Acute Ischemic Stroke Patients? (P2.278)
Conclusion: In patients who are not candidates for IV tPA eptifibatide may be a safe and efficacious alternative. None of the patients who were started on eptifibatide had bleeding complications and they had a statistically significant improvement in their level of disability and stroke severity at discharge. To better evaluate the efficacy of eptifibatide, a larger, prospective study should be initiatedDisclosure: Dr. Korya has nothing to disclose. Dr. Moussavi has nothing to disclose. Dr. Mehta has nothing to disclose. Dr. Brar has nothing to disclose. Dr. Chahal has nothing to disclose. Dr. Daniel has nothing to disclos...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Mehta, S., Moussavi, M., Korya, D., Brar, J., Chahal, H., Daniel, J., Samaan, M., Panezai, S., Kirmani, J. Tags: Acute Therapy: Thrombolysis and Adjuvant Therapy Source Type: research

Eptifibatide Is Safe and May Improve Outcomes in Stroke Patients Undergoing Thrombectomy after Receiving IVtPA (P2.276)
CONCLUSION: The addition of eptifibatide bolus followed by a continuous drip for a mean of 24-hours to IV tPA/thrombectomy was associated with a significantly better 24-hour post-procedure outcome and is safe. This could be due to suppression of inflammation and potential prevention of rethrombosis after treatment. A larger prospective trial is warranted to corroborate our findings.Disclosure: Dr. Mehta has nothing to disclose. Dr. Moussavi has nothing to disclose. Dr. Korya has nothing to disclose. Dr. Brar has nothing to disclose. Dr. Chahal has nothing to disclose. Dr. Kondapalli has nothing to disclose. Dr. Samaan has ...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Chahal, H., Mehta, S., Moussavi, M., Korya, D., Brar, J., Kondapalli, S., Samaan, M., Shaikh, A., Kalola, R., Song, Y.-B., Kirmani, J. Tags: Acute Therapy: Thrombolysis and Adjuvant Therapy Source Type: research

Eptifibatide use in ischemic stroke patients undergoing endovascular thrombectomy: A matched cohort analysis
ConclusionIn this single-center analysis, EPT use during EVT was associated with a significantly higher rate of PH1/PH2 grade hemorrhages, but not with differences in sICH, 24-h NIHSS, or 90-day mortality. Randomized prospective trials are needed to determine the safety and efficacy of EPT in this population.
Source: Frontiers in Neurology - September 27, 2022 Category: Neurology Source Type: research

E-008 Safety and efficacy of eptifibatide in acute ischemic stroke requiring extracranial carotid artery stenting
ConclusionsEptifibatide may have a role in the management of acute stroke requiring carotid stenting. Caution may be required in those with established infarct on presentation imaging.Disclosures M. Waters: None. J. Vargas: None. R. Turner: None. A. Turk: None. I. Chaudry: None.
Source: Journal of NeuroInterventional Surgery - July 30, 2023 Category: Neurosurgery Authors: Waters, M., Vargas, J., Turner, R., Turk, A., Chaudry, I. Tags: SNIS 20th annual meeting electronic poster abstracts Source Type: research

Safety and efficacy of eptifibatide in acute ischemic stroke requiring extracranial carotid artery stenting
CONCLUSIONS: Eptifibatide may have a role in the management of acute stroke requiring carotid stenting. Caution may be required in those with established infarct on presentation imaging.PMID:37574792 | DOI:10.1177/15910199231193928
Source: Interventional Neuroradiology - August 14, 2023 Category: Radiology Authors: Michael J Waters Jan Vargas Aquilla Turk Imran Chaudry Raymond D Turner Source Type: research